Background: Early-onset inflammatory bowel disease (IBD) is generally aggressive, with a high probability of complications and need of surgery.
both in terms of disease extension and progression, with a high probability of complications and surgery; moreover, the disease proves much more aggressive the earlier the onset is. 1 Pharmacological therapy of IBD is primarily aimed at inflammation treatment and control, through the use of drugs able to induce and maintain disease remission. 3 Drugs currently available for induction and maintenance therapy of pediatric IBD, such as glucocorticoids, azathioprine, and biologics, are less effective in early-onset cases. 4 For azathioprine, response to standard doses is reduced in early-onset patients in comparison with those with onset at age older than 6 years: Open studies showed that a higher dosage of azathioprine compared with conventional regimens should be used in patients with early-onset IBD to achieve better response. 5, 6 Azathioprine is a prodrug and requires bioactivation to thioguanine nucleotides (TGNs), through a complex pathway of enzymatic reactions, overlapping with the salvage pathway for nucleotides synthesis. Polymorphisms in genes for enzymes involved in the metabolism of azathioprine influence treatment's efficacy and toxicity. 7 Thiopurine methyltransferase (TPMT) influences substantially azathioprine metabolism at several steps, thereby altering the formation of active TGNs. 8 In patients with genetic variants leading to reduced activity of TPMT, the metabolic pathway of azathioprine is shifted in the direction of active TGNs. 9 Polymorphisms in TPMT have been associated with an increased risk for azathioprine-related adverse events in patients with IBD. 10 The determination of azathioprine metabolites concentrations is considered to be an important tool for individualization of thiopurine therapy to verify patients' compliance and adequate exposure to active metabolites. 11 We, therefore, hypothesized that patients with early-onset IBD may present an altered azathioprine pharmacokinetics in comparison with patients with nonearly-onset disease, leading to decrease sensitivity to azathioprine. The aim of this study was then to evaluate azathioprine doses, metabolite concentrations, and their associations with age in patients with early-onset pediatric IBD in comparison to patients with nonearly-onset pediatric IBD.
MATERIALS AND METHODS

Ethical Considerations
The study was approved by the local ethical committees, and appropriate informed consent was obtained from all patients or their parents or tutors.
Patients and Eligibility Criteria
In this study, 68 patients with IBD were enrolled by the participating centers between October 2014 and September 2015. The inclusion criteria were age up to 6 years for cases and older than 12 years and younger than 18 years for controls, previous diagnosis of IBD and treatment with azathioprine for at least 3 months, and stable dose of azathioprine for at least 1 month. The exclusion criteria were patients with ileostomy or colostomy, disease needing surgery, fulminant UC or toxic megacolon, and contemporary presence of other noncontrolled pathologies, concomitant therapy with anti-tumor necrosis factor biological agents (infliximab or adalimumab). Other cotreatments, such as aminosalicylates, glucocorticoids, or enteral therapy, were allowed.
The patients enrolled were all the eligible consecutive cases taking azathioprine at the participating centers in the timeframe of the study. For each case, the first 3 consecutive controls enrolled in each center, matched on IBD diagnosis, were selected.
Therapeutic Protocol and Sample Collection
This case-control study was noninterventional, and patients were treated according to standard care and enrolled crosssectionally from those treated in each participating hospital. Patients were treated with a dose escalating strategy to reduce the risk of adverse events starting, however, from a relatively high dose (median of 2 mg/kg). At subsequent follow-up visits, the dose was increased or reduced so as to obtain the optimal clinical response; the criteria used to increase or reduce the dose of azathioprine were the level of disease activity and laboratory parameters used to monitor azathioprine toxicity (in particular leukocytes, erythrocytes and platelets counts, hemoglobin concentration, mean corpuscolar volume, liver enzymes such as alanine transaminase, aspartate transaminase, and gamma-glutamyl transferase and amylase levels).
Blood samples, collected for measuring azathioprine metabolites, TPMT activity, and for genotyping, were taken at the first clinic visit occurring after at least 3 months of therapy and 1 month on stable azathioprine dose. Timing of sample collection was independent from clinical response status, and results of pharmacokinetic analysis did not affect clinicians in their therapeutic choices.
Definition of Clinical Response
Clinical response was assessed, using Pediatric Crohn's Disease Activity Index (PCDAI) 12 and Pediatric Ulcerative Colitis Activity Index (PUCAI), 13 respectively, for patients with CD and UC, at the time of blood sample collection for the metabolites' measurement. Disease was considered inactive if the activity index was lower than 10 at the time of sample collection. Successful therapy or inactive disease was not among the inclusion criteria.
Measurement of Azathioprine Metabolites
Azathioprine metabolites (TGN and methylmercaptopurine nucleotides, MMPN) were measured at the Department of Life Sciences, University of Trieste in patients' erythrocytes using a high-performance liquid chromatography (HPLC) assay by Dervieux et al. 14 Blood samples were centrifuged for collection of erythrocytes, as previously described; erythrocytes were stored at 2808C until analysis, which was performed within a month from collection. Metabolites concentration is expressed as pmol/8 · 10 8 erythrocytes. The ratio between TGN and the dose of azathioprine was calculated considering for each individual measurement the dose the patients were taking the day the blood sample for the metabolites assessment was collected.
Measurement of TPMT Activity
TPMT activity was measured for all patients at the Department of Life Sciences, University of Trieste using an HPLC assay based on in vitro conversion of mercaptopurine to methylmercaptopurine, using S-adenosyl-methionine as the methyl donor. 15 TPMT activity is expressed as nmol of methylmercaptopurine produced by lysates of patients' erythrocytes, containing 1 mg of hemoglobin, during 1 hour of incubation at 378C in the presence of mercaptopurine. TPMT activity was measured concurrently to azathioprine metabolites, if the amount of patients' erythrocytes was sufficient.
Genotypes
Genomic DNA was extracted from peripheral blood samples using a commercial kit (SIGMA, Milan, Italy), to characterize the most relevant genetic polymorphisms in the candidate gene TPMT (rs1800462, rs1800460, and rs1142345), using TaqMan assays (Thermoscientific, Milan, Italy).
Statistical Analysis
Statistical analysis was performed using software R (version 3.2.4). The association between pharmacological phenotypes of interest (i.e., therapeutic response, dose of azathioprine, TGN metabolites concentrations, MMPN metabolites concentrations, ratio TGN/dose, TPMT activity, and concomitant therapies) and the considered covariates (i.e., demographic variables including age-group classification, IBD type, and TPMT genotypes) was evaluated in a univariate analysis using generalized linear models of appropriate family (Gaussian/analysis of variance [ANOVA] for continuous and binomial/logistic regression for categorical variables). In these univariate analyses, the dependent variable was the pharmacological phenotype of interest and the independent variable the demographic, clinical, or pharmacogenetic covariate.
Multivariate analysis was performed to test the independence of the significant effects identified in univariate analyses on the phenotypes considered; for this multivariate analysis, generalized linear models of the appropriate family were used combining covariates significant in the univariate analysis as the independent variables. For all parametric analyses (i.e., linear models used in the univariate analysis and the multivariate analysis), normality of the phenotype was tested by the Shapiro test and log10 or Box-Cox transformation was applied if needed, to adjust the normality of the distribution.
RESULTS
Patients Enrolled and Samples Collected
This study recruited 17 early-onset patients with IBD, matched to 51 patients with later-onset pediatric IBD, considered as controls. Demographic and clinical characteristics are reported in Table 1 . From October 2014 to September 2015, peripheral blood samples have been collected to measure azathioprine metabolites. Among these, 27 were obtained during treatment with azathioprine alone and 41 during treatment with azathioprine and other medications and in particular: 26 with an aminosalicylate, 6 with a glucocorticoid, 6 with an aminosalicylate and a glucocorticoid, 2 with an aminosalicylate and an antibiotic, and 1 with enteral nutrition; no significant difference could be observed for cotreatments between cases and controls. In particular, frequency of patients taking aminosalicylates with azathioprine was similar between cases and controls, respectively (41.2% versus 52.9%, P value logistic regression ¼ 0.40). At the time of the evaluation, none of the patients was on allopurinol, furosemide, or any other medication that could interfere with thiopurine metabolism.
Genotyping
TPMT genotyping is available for all cases and 48 controls; in 3 control patients, genotyping could not be performed because of technical reasons. All polymorphisms considered were in accordance with Hardy-Weinberg equilibrium, and Among these, the early-onset patient and 1 nonearly-onset patient presented also the rs1800460 (G460A) variant in heterozygous form. No patient presented the rs1800462 (G238C) variant. Therefore, in terms of variant alleles, 2 patients (1 case and 1 control) were heterozygous for TPMT*3A, whereas 1 control was heterozygous for TPMT*3C. All other 62 patients with available DNA for genotyping were considered homozygous for the TPMT*1 allele.
Clinical Efficacy in Patients with Early-onset IBD in Comparison with Nonearly-onset Patients
Clinical response was determined: Frequency of patients in remission was not different among early-onset and control groups, respectively (82% and 84%, odds ratio early onset versus nonearly-onset ¼ 0.76, 95% CI, 0.18-3.89, P value logistic regression ¼ 0.72).
Azathioprine Doses and Metabolites in Patients with Early-onset IBD in Comparison with Nonearly-onset Patients
Early-onset patients required higher doses of azathioprine (median 2.7 versus 2.0 mg$kg$ 21 $d 21 , P value ANOVA ¼ 1.1 · 10 24 , Fig. 1 ). This difference was present even considering separately patients with CD and UC (see For all covariates besides azathioprine dose, considering patients with CD and UC separately, the trends were similar to those described in the grouped patients with pediatric IBD, even if no significant difference can be calculated, likely because of the reduction in population size in the separated groups (data not shown).
TPMT Activity in Patients with Early-onset IBD in Comparison with Nonearly-onset IBD Patients
TPMT activity could be measured in a subset of patients for which sufficient blood sample was available after the quantification of thiopurine metabolites, in particular 9 early-onset and 27 nonearly-onset IBD patients. This population was representative of the whole group because no demographic variable was different between this subgroup of patients and the whole study population in terms of the demographic, clinical, and pharmacological variables. Interestingly, early-onset patients presented higher activity of TPMT (Fig. 5 , median 476 versus 350 nmol of methylmercaptopurine/mg hemoglobin/h, P value ANOVA ¼ 0.046).
Additional Univariate Analysis on Demographic, Clinical, and Pharmacogenetic Covariates and Azathioprine Pharmacokinetics
Type of IBD showed a fully significant effect on the median TGN or TGN/dose ratio in our population, respectively FIGURE 2. The boxplots show TGN concentrations (pmol/8 · 10 8 erythrocytes) in patients with early-onset IBD (aged , 6 yr) or nonearly-onset IBD (aged . 12 and ,18 years); empty and solid points display TGN concentration values for patients with wild-type and variant TPMT, respectively; P-value is from ANOVA. TGN concentration values were log-transformed to adjust normality. 
Multivariate Analysis Evaluating Independence of the Effects of the Genotypes on Azathioprine Metabolites Concentrations or Dose
For azathioprine dose, TGN concentrations, MMPN concentrations, and TPMT activity, no multivariate analysis was performed because only 1 covariate had a fully significant effect in a univariate analysis. For TGN/dose ratio, the multivariate generalized linear model showed that early-onset IBD, UC type of IBD, and variant TPMT genotype are independent determinants of increased concentration of TGN metabolites per unit of azathioprine administered. Detailed results of this multivariate analysis are reported in Table 2 .
DISCUSSION
In this study, performed on children with IBD, we demonstrate for the first time that early-onset IBD patients (aged , 6 years) have profound differences in azathioprine pharmacokinetics in comparison with nonearly-onset patients (aged between 12 and 18 years). In particular, the ratio of active TGN metabolites per unit of daily azathioprine dose is significantly reduced in early-onset patients. This could explain the much higher doses required by early-onset patients, to achieve similar efficacy. Indeed, the larger doses administered resulted in similar concentration of active metabolites in early-onset and older children with IBD. Interestingly, early-onset IBD was associated with increased activity of TPMT, the main enzyme involved in azathioprine biotransformation, further supporting the hypothesis that patients with early-onset IBD have increased inactivation of thiopurines and, therefore, may be less sensitive to the drug than nonearly-onset patients.
Azathioprine is frequently used in IBD and is important to maintain remission; however, a significant proportion of patients does not respond to therapy or develops important adverse events. 16, 17 The causes for this interindividual variability in response to azathioprine are not completely understood; however, a consistent amount of evidence relates variability in azathioprine response to interindividual differences in the metabolism of the medication, that are due, at least in part, to genetic polymorphisms of relevant enzymes, 9 such as TPMT and NUDT15, which are particularly important in Asian patients. 18 It has been previously described that the activity of one of the most relevant enzymes involved in azathioprine biotransformation, TPMT, is elevated in newborns, in comparison with children, 19 and in younger children in comparison with older ones and adults. 20 The observation of higher TPMT activity in younger children has not been supported by all published studies; 21 however, most of the studies not describing a relevant age-effect on TPMT were focused on adult patients and spanning all age groups, with the addition of potential confounders. 22 Many studies in children on azathioprine pharmacokinetics, especially those in patients with IBD, are still underpowered; 23 therefore, this study is the first one to clearly present the differences in azathioprine pharmacokinetics of patients with early-onset IBD. However, studies performed in larger populations of patients with acute lymphoblastic leukemia also support lack of efficacy of thiopurines in younger patients, due to reduced concentration of active TGN metabolites and potentially increased TPMT activity. 24 Indeed, a recent large study on TPMT activity in children with leukemia confirmed that younger age is associated with increased TPMT activity. 25 Our current study is noninterventional; therefore, the potential clinical application of its findings is limited. However, the practice of administering high doses of thiopurines in earlyonset IBD, to improve therapeutic efficacy, is common and should be explored by properly designed randomized controlled trials to define strategies to further improve therapy with thiopurines in this age group. One may assume that an integrated approach including nongenetic (e.g., developmental) and genetic factors may improve our understanding of azathioprine response. 26 On these bases, there is a strong clinical recommendation to elucidate the impact of higher azathioprine dosage (3.5 mg$kg 21 $d 21 ) in pediatric patients with early-onset IBD by a randomized prospective "dose finding" trial to develop an age-specific formulation for a chronic highly debilitating disease, especially for patients with early onset. Liquid formulations for younger children may also be preferable and could be considered. 27 In this study, we do not provide evidence on the molecular mechanism by which TPMT is increased in early-onset IBD. Epigenetic mechanisms, in particular methylation of gene promoters, have been proposed in ontogenesis of enzymes responsible for drug biotransformation, 28 such as cytochromes. 29 Innovative studies could be performed to test whether similar age-dependent epigenetic mechanisms occur also for TPMT promoter methylation. 30 Moreover, besides increased TPMT activity, also other enzymes involved in azathioprine metabolism, such as glutathione transferases, could be reduced in patients with early onset and increased during development, affecting azathioprine pharmacokinetics and efficacy, and could be evaluated in further studies. 9, 17 In addition to differences in biotransformation, other pharmacokinetic factors, influenced by age, may contribute to the requirement for higher azathioprine doses described by our study, such as changes in absorption and bioavailability. 5, 31 TPMT activity might have been affected by concomitant mesalazine treatment 32 ; however, frequency of patients in therapy with mesalazine was not significantly different between cases and controls. Azathioprine therapy itself could have influenced TPMT activity: indeed because cases were on higher doses of azathioprine, and TPMT activity might be raised because of that 33 ; however, induction of TPMT activity by thiopurine treatment in patients with IBD is controversial. 34 Finally, our early-onset population did not include patients with very early-onset disease (younger than 1 yr): studies focusing in this important although rare patients' population could be considered. 2 One strength of this study is that all laboratory tests for azathioprine metabolites, TPMT activity, and TPMT genotype were conducted at the same centralized laboratory. 35 The effect size represents the increase (positive value) or decrease (negative value) in the value of the dependent variable for each independent variable listed.
b P values are from a generalized linear model.
In conclusion, this study demonstrates that patients with early-onset IBD present an increased inactivating azathioprine metabolism, possibly because of elevated activity of the enzyme TPMT.
